title: The balm of Gilead: is the provision of treatment to those who seroconvert in HIV prevention trials a matter of moral obligation or moral negotiation?
abstract: Must treatment be provided to subjects who acquire HIV during the course of a prevention study? An analysis of ethical foundation, regulation, and recent argumentation provides no basis for the obligation. We outline an alternative approach to the problem based on moral negotiation.
authors.affiliation: Department of Philosophy, Talbot College, the University of Western Ontario, Canada.
authors.forename: Charles
authors.initials: C
authors.lastname: Weijer
authors.forename: Guy J
authors.initials: GJ
authors.lastname: Leblanc
mesh_terms: D019380:Anti-HIV Agents; D002986:Clinical Trials as Topic / Q000941:ethics*; D035881:Compensation and Redress / Q000941:ethics*; D003906:Developing Countries; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control*; D006679:HIV Seropositivity; D006801:Humans; D007391:International Cooperation; D008297:Male; D028681:Moral Obligations; D017008:Negotiating
chemical_list: D019380:Anti-HIV Agents